Romualdo Barroso, Medical Oncologist, Head of Research in Oncology and National Leader of Breast Cancer shared a post on X:
- “We are pleased with the publication of the Neo-Real study (GBECAM-0123), which evaluated RWD from 10 Brazilian centers, comparing ddAC vs q3wAC regimen in pts with TNBC treated with pembrolizumab plus CT in the neoadjuvant setting.
- A pCR was observed in 65.4% with ddAC and 58.7% with q3w AC (P = 0.260), while RCB 0-1 occurred in 82.4% and 73.5%, respectively (P = 0.115). Pts with stage III had a higher pCR with ddAC (59% vs 40%, P = 0.155), while pCR rates were similar regardless of AC regimen in stage II.
- While no significant disparities in drug discontinuation was noted, ddAC showed a trend towards higher rates of grade ≥3 AE (40.5% vs. 30.7%, P = 0.092). We hope to present survival outcomes in the future.”
Authors: Rakesh Kumar Sharma, Ajay Gogia, Svs Deo, Dayanand Sharma, Sandeep Mathur, and Hari Krishna Raju Sagiraju
Source: Romualdo Barroso/X